Anders Krarup‐Hansen

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.1K citations · Full text

Metastatic Soft-tissue Sarcoma, Versus Intensified Doxorubicin, Oncology +7

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine et al. · The Lancet Oncology · 2017 · 293 citations · Full text

Medicine, Randomised Phase 3, Metronomic Therapy +7

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

William D. Tap, Andrew J. Wagner, Patrick Schöffski et al. · JAMA · 2020 · 288 citations · Full text

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi et al. · The Lancet Oncology · 2011 · 236 citations

Soft-tissue Sarcoma, Pathology, Phase 2 +2

Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies

Anders Krarup‐Hansen, S. Helweg‐Larsen, H. Schmalbruch et al. · Brain · 2006 · 162 citations

Peripheral Nerve Injury, Pain Medicine, Neuropathic Pain +20